An observational study in Gestational Diabetes Mellitus (GDM) and Non-communicable Chronic Diseases, sponsored by Yang ZHANG. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Yang ZHANG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Diabetes, Gestational with a site in China — 19 open to participants now, 23 under way, none of them phase 3. Diabetes, Gestational · China.
Among the 68 studies in Diabetes, Gestational with a site in China, this one is the 17th largest by planned enrollment of the 29 observational ones that give a count, is one of 2 that started in 2025, is one of 29 observational ones, reaches primary completion later than 15 of the 22 other live ones, and was the 63rd registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →19 of the 68 studies in Diabetes, Gestational with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–40 · Women only · Healthy volunteers
Peking University · Sites in China
Ages 18+ · Healthy volunteers
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–50 · Women only
Peking Union Medical College Hospital · Sites in China
Ages 18+ · Women only
Peking Union Medical College Hospital · Sites in China
Ages 20–45 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 175 across 290 observational studies indexed under Diabetes, Gestational.
Median enrollment 291 across the 39 interventional studies, 1,122 across the 29 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 68 has an industry lead sponsor. The 10 most frequent:
Yang ZHANG is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Yang ZHANG has 1 study filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes, Gestational with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06234332Peking UniversityPeking University Birth Cohort in Weifang (PKUBC-WF) | 2026-12-31 |
| NCT07119177Yang ZHANGLong-term Evaluation of Gestational Endocrine & Metabolic Dynamics | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 68 studies in Diabetes, Gestational with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gestational diabetes mellitus (GDM) is the most common complication and metabolic disorder during pregnancy, with clear risks to both the mother and fetus. In recent years, the long-term chronic diseases and poor prognosis in GDM women after delivery, as well as the risk of obesity and metabolic disorders in their offspring, have become key research topics. However, due to the long duration of GDM's impact on both the mother and offspring and its involvement in multiple disciplines, high-quality cohort studies are scarce. As a result, there is no definitive conclusion regarding the high-risk factors, natural progression, key mediators, timing of interventions, and targets for GDM's long-term effects on mothers and their offspring. This project intends to initiate a prospective follow-up study, establish a specialized cohort for the long-term effects of GDM on both mothers and their offspring, and complete the characterization of the natural course of non-communicable chronic diseases (NCDs) in GDM women and their offspring. The study will also explore high-risk and mediator factors, and develop predictive models. The goal is to provide education, postpartum follow-up, monitoring, and possibly initiate primary prevention for GDM women to reduce the long-term NCD risks, ultimately improving their life expectancy and providing a theoretical basis for intervention.
Inclusion Criteria:
Exclusion Criteria:
Gestational diabetes mellitus (GDM) patients who delivered at Peking University First Hospital between 2007 and 2016 will be identified through electronic medical record searches. We intend to enroll a total of 800 GDM patients meeting the above inclusion/exclusion criteria and their offspring.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevalence of type 2 diabetes mellitus
Subjects who meet either criterion 1 or 2 will be considered to have type 2 diabetes: 1. With classical symptoms of diabetes: if any one of the following is met: Random plasma glucose ≥ 11.1 mmol/L, or Fasting plasma glucose (FPG) ≥ 7.0 mmol/L, or 2-hour plasma glucose during an oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L, or HbA1c (glycated hemoglobin) ≥ 6.5%. 2. Without classical symptoms of diabetes: either two glucose indicators measured at the same time point reaching or exceeding diagnostic thresholds, or Glucose indicators measured at two different time points reaching or exceeding diagnostic thresholds (excluding random plasma glucose).
Time frame: At 8-17 years postpartum
Prevalence of metabolic syndrome
Individuals meeting 3 or more of the following 5 components will be considered to have metabolic syndrome: 1. Waist circumference ≥ 85 cm in women; 2. FPG ≥ 6.1 mmol/L and/or 2hPG ≥ 7.8 mmol/L, and/or previously diagnosed diabetes; 3. Blood pressure ≥ 130/85 mmHg, and/or previously diagnosed hypertension and treated; 4. Fasting TG ≥ 1.7 mmol/L; 5. Fasting HDL-C \< 1.04 mmol/L.
Time frame: At 8-17 years postpartum
Prevalence of cardiovascular diseases
The presence of any of the following items is considered indicative of cardiovascular disease: 1. Inquire about history(definitively diagnosed by a qualified physician) of cardiovascular diseases, including coronary heart disease, hypertension and arrhythmia. 2. Quantify coronary artery calcium score via non-contrast CT scan, \> 100 indicates elevated risk for coronary heart disease. 3. With Framingham Cardiovascular Risk Score calculated for non-diseased individuals(men ≥15 and women ≥18 are classified as high cardiovascular risk). 4. Perform an electrocardiogram for diagnose of arrhythmia. 5. ABI, TBI, and baPWV are utilized to assess arteriosclerosis in the extremities, ABI \< 0.9 or TBI \< 0.7 or baPWV \> 1400 cm/s is diagnostic of peripheral arterial disease. 6. Carotid ultrasonography is performed to assess carotid plaque.
Time frame: At 8-17 years postpartum
Prevalence of cognitive function
Inquire about history of cognitive function(definitively diagnosed by a qualified physician).
Time frame: At 8-17 years postpartum
Prevalence of renal disease
Subjects who meet criterion 1 or 2 will be considered to have renal disease: 1. Serum creatinine\>133μmol/L. 2. Urinary microalbumin/urinary creatinine\>30mg/g.
Time frame: At 8-17 years postpartum
Prevalence of anxiety
Assessed by standardized depression and anxiety scales \[Zung Self-rating Anxiety Scale(SAS)\]. Anxiety Severity Classification: Normal: \<50, Mild Anxiety: 50-59, Moderate Anxiety: 60-69, Severe Anxiety: ≥70
Time frame: At 8-17 years postpartum
Thyroid Function
Assessed via measurement of thyroid hormone levels
Time frame: At 8-17 years postpartum
Bone Density
Assessed via quantitative ultrasound (QUS) measurement of T-scores and Z-scores at the bilateral distal radius.
Time frame: At 8-17 years postpartum
Offspring Growth and Development
Growth curve values persistently below the 3rd percentile (P3) or above the 97th percentile (P97), as defined by the \*China Height and Weight Percentile Curves for Children and Adolescents Aged 2-18 Years\* developed by the Growth and Development Research Laboratory, Capital Institute of Pediatrics, were considered indicative of abnormal growth
Time frame: At 8-17 years old
CAIDE Dementia Risk Score
With CAIDE Dementia Risk Score calculated for individuals without history of cognitive function.
Time frame: At 8-17 years postpartum
N-acetyl-β-D-glucosaminidase (NAG)
\>12U/L is considered early-stage renal tubule injury.
Time frame: At 8-17 years postpartum
Prevalence of depression
Assessed by standardized depression and anxiety scales \[Zung Self-Rating Depression Scale(SDS)\]. Depression Severity Classification: Normal: \<53, Mild Depression: 53-62, Moderate Depression: 63-72, Severe Depression: ≥73
Time frame: At 8-17 years postpartum
Hyperuricemia
Serum uric acid levels exceed 420 μmol/L.
Time frame: At 8-17 years postpartum
Hyperhomocysteinemia
Serum homocysteine \>15 μmol/L
Time frame: At 8-17 years postpartum
Fatty liver disease
Liver Transient Elastography (CAP) Fat Attenuation Grading: Normal: \<244 dB/m Mild Hepatic Steatosis: 244-269 dB/m Moderate Hepatic Steatosis: 269-296 dB/m Severe Hepatic Steatosis: \>296 dB/m
Time frame: At 8-17 years postpartum
Body fat percentage:
18%-28% is considered normal.
Time frame: At 8-17 years postpartum
Kutcher Adolescent Depression Scale (11-item version, KADS-11)
Range: 0-33; Higher scores indicate worse status. A total score ≥9 suggests a depressive state.
Time frame: 11-17 years old
Swanson, Nolan, and Pelham Rating Scale (SNAP-IV)
Items 1-9 constitute the Attention Deficit subscale (range: 0-27, ≤13: Normal); Items 10-18 constitute the Hyperactivity-Impulsivity subscale (range: 0-27, ≤13: Normal); Items 19-26 constitute the Oppositional Defiant subscale: Abnormality is defined as ≥4 items scored as 2 or 3.
Time frame: 10-18 years old
Screen for Child Anxiety Related Emotional Disorders (SCARED)
Range: 0-82; Higher scores indicate worse condition; a total score ≥25 suggests anxiety.
Time frame: 10-18 years old
Social Anxiety Scale for Children (SASC)
Range: 0-20; Higher scores indicate worse condition; no standardized cutoff.
Time frame: 10-18 years old
Plan to share: Yes — The clinical information of the participants and the primary outcome data of the LEGEND study will be shared
Supporting information: Study protocol, Clinical study report
Time frame: IPD will be available half year after the last participants finished the study
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 21 months is below that.
Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.